drugset / Trial / NCT06802146
Early Intervention in High Risk CCUS
Phase 0
Recruiting
108 enrolled
Lachelle D. Weeks, MD, PhD
Astex Pharmaceuticals, Inc. · collabBreak Through Cancer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Timeline
- Start
- 2025-02-07
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | 100 mg | Oral |
| Subject | Decitabine | Small molecule | 10 mg | Oral |